Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
|
|
- Marilyn Hutchinson
- 8 years ago
- Views:
Transcription
1 Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential conflict of interest in relation to this presentation Opioid Withdrawal Syndrome Three categories of symptoms: CNS irritability Anxiety, agitation, tremors, seizures, etc. GI dysfunction Vomiting, diarrhea, poor feeding Autonomic dysfunction Fever, sweating, hypertension, yawning etc. Diagnosis of exclusion 2 Crit Care Med. 2008:36:8:
2 Risk Factors for Withdrawal Prolonged opioid use (> 5-7 days) Abrupt discontinuation of opioids High opioid total cumulative doses Fentanyl > 2.5 mg/kg total dose 3 Crit Care Med. 2008:36:8: Intensive Care Med 2007;33: Withdrawal Assessment Tool (WAT-1) 83 pediatric patients Score 0-12 < 3: low chance of withdrawal > 3: higher chance of withdrawal Study published showing no age differences and good reproducibility 4 Pediatr Crit Care Med 2008;9(6):
3 Withdrawal Assessment Tool (WAT-1) 0-12 scoring system (No=0, Yes=1) Patient record Loose watery stool, vomiting, temperature >37.8 C Pre-stimulus Awake/distressed, tremor, sweating, repetitive movements, yawning/sneezing Stimulus Startle to touch, increased muscle tone Post-stimulus Time to calm state (< 2 mins=0, 2-5 mins=1, > 5 mins=2) 5 Pediatr Crit Care Med 2008;9(6): Learning Question 1 What are the different components of the withdrawal assessment tool (WAT-1)? A. Patient record B. Pre-stimulus C. Stimulus D. All of the above 6 3
4 Learning Question 1 What are the different components of the withdrawal assessment tool (WAT-1)? A. Patient record B. Pre-stimulus C. Stimulus D. All of the above 7 Pharmacologic Weaning Options Oral opioids: Methadone vs. Morphine 4
5 Oral Weaning Options Methadone Advantages High bioavailability Prolonged half-life Disadvantages Drug-drug interactions Drug accumulation Unpredictable opioid equivalent doses Black-box warning 9 Acta Anaesthesiol Scand 2008;52: Oral Weaning Options Morphine Advantages Predictable pharmacokinetic profile Disadvantages Drug accumulation in renal dysfunction Opioid equivalent dosing Few drug-drug interactions 10 Pain Physician 2008:11:S133-S153 5
6 Learning Question 2 What is a limitation for using methadone in opiate withdrawal? A. Drug accumulation after prolonged dosing B. Short half-life C. Excellent oral bioavailability D. No black-box warnings 11 Learning Question 2 What is a limitation for using methadone in opiate withdrawal? A. Drug accumulation after prolonged dosing B. Short half-life C. Excellent oral bioavailability D. No black-box warnings 11 6
7 Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Primary Investigator: Jennifer Kuhns, Pharm.D. Secondary Investigators: Joanna Ditouras, Pharm.D. and Kevin Valentine, M.D. Detroit Medical Center Children s Hospital of Michigan Study Design Institutional review boards at DMC and Wayne State University approved the study Single-center prospective observational study with retrospective historical controls Pediatric intensive care unit (PICU) patients admitted to CHM January 1 st, 2010 through March 1 st, 2013 Retrospective: January 1 st September 30 th 2012 Prospective: October 1 st March 1 st
8 Purpose Purpose To conduct a pilot study comparing a prospective morphine taper to a historical methadone taper previously used in the PICU 16 Outcomes Primary outcome Incidence of opioid withdrawal Utilizing WAT-1 Secondary outcomes Duration/doses of medication therapy Cost of therapy Length of ICU/hospital stay Benzodiazepine doses/concurrent taper 17 8
9 Inclusion Criteria Patients < 18 years of age Admitted to the PICU between January 1, 2010 and March 1, 2013 Methadone or morphine taper after prolonged opioid continuous infusion of > 5 days Methadone taper (01/01/ /30/2012) Morphine taper (10/01/ /01/2013) 18 Exclusion Criteria Patients > 18 years of age Patients receiving chronic opioids prior to current PICU admission 19 9
10 Methods All patients were started on protocol if they had been on continuous infusion (CI) opioids > 5 days 10 day wean 5-10 days on CI 20 day wean 11+ days on CI 20 Morphine Protocol Calculate the original daily dose (ODD): Morphine oral mg ODD= (Morphine CI mg daily dose) x (3) CI wean: Day 1: Wean drip by 33% every 8 hours Day 2: CI drip is stopped 21 10
11 22 10 DAY ORAL MORPHINE WEAN DAY ORAL 1 Divide ODD every 4 hours 2 Decrease day 1 TDD by 10% and administer every 4 hours 3 Decrease day 2 TDD by 10% and administer every 6 hours 4 Decrease day 3 TDD by 10% and administer every 6 hours 5 Decrease day 4 TDD by 10% and administer every 8 hours 6 Decrease day 5 TDD by 10% and administer every 8 hours 7 Decrease day 6 TDD by 10% and administer every 12 hours 8 Decrease day 7 TDD by 10% and administer every 12 hours 9 Decrease day 8 TDD by 10% and administer every 24 hours 10 Decrease day 9 TDD by 10% and administer every 24 hours 11 Discontinue morphine ODD=Original daily dose TDD=Total daily dose DAY ORAL MORPHINE WEAN DAY ORAL 1-2 Divide ODD every 4 hours 3-4 Decrease day 2 TDD by 10% and administer every 4 hours 5-6 Decrease day 4 TDD by 10% and administer every 6 hours 7-8 Decrease day 6 TDD by 10% and administer every 6 hours 9-10 Decrease day 8 TDD by 10% and administer every 8 hours Decrease day 10 TDD by 10% and administer every 8 hours Decrease day 12 TDD by 10% and administer every 12 hours Decrease day 14 TDD by 10% and administer every 12 hours Decrease day 16 TDD by 10% and administer every 24 hours Decrease day 18 TDD by 10% and administer every 24 hours 21 Discontinue morphine ODD=Original daily dose TDD=Total daily dose 11
12 Methods WAT-1 scale to be used Rescue doses Contact physician if WAT-1 > 3 Per physician discretion Morphine 0.1 mg/kg IV x 1 dose 20 day 10 day wean Zero rescue doses and two consecutive WAT-1 scores < 3 10 day 20 day wean 4+ rescue doses in 24 hours and two consecutive high WAT-1 scores (> 3) 24 Statistical Analysis Sample size Pilot study Fisher s exact test or Pearson Chi-Square Demographic and visit characteristics Statistical significance p value < 0.05 Mann-Whitney U Test PICU/hospital days Morphine/methadone doses/taper days Continuous infusion days Opioid/benzodiazepine rescue doses 25 12
13 Sample Size Retrospective N=62 10 day wean N=6 (25%) Prospective N=24 20 day wean N=18 (75%) Included N=14 (78%) Excluded** N=4 (22%) 26 **Patients were excluded from primary and secondary statistical analysis if they did not finish their morphine wean by 03/01/2013 Patient Characteristics Baseline Characteristics Mean (range) Retrospective (n=62) Prospective (n=24) P-value Age (years) 1.47 ( ) 0.83 ( ) p=0.29 Sex Male 27 (43.5%) Female 35 (56.5%) Male 6 (25%) Female 18 (75%) p=0.14 Height (cm) 67.1 ( ) 58.8 (44-127) p=0.12 Weight (kg) 9.35 ( ) 6.27 ( ) p=0.12 Service CV 35 (56.5%) Med 27 (43.5%) Admitting Dx Cardiac 33 (53.2%) Resp 19 (30.6%) Other 10 (15.3%) CV 20 (83.3%) Med 4 (16.7%) Cardiac 6 (25%) Resp 15 (62.5%) Other 3 (12.5%) p=0.03 p=
14 Patient Characteristics Baseline Characteristics Mean (range) Retrospective (n=62) Prospective (n=24) P-value Age (years) 1.47 ( ) 0.83 ( ) p=0.29 Sex Male 27 (43.5%) Female 35 (56.5%) Male 6 (25%) Female 18 (75%) p=0.14 Height (cm) 67.1 ( ) 58.8 (44-127) p=0.12 Weight (kg) 9.35 ( ) 6.27 ( ) p=0.12 Service CV 35 (56.5%) Med 27 (43.5%) Admitting Dx Cardiac 33 (53.2%) Resp 19 (30.6%) Other 10 (15.3%) CV 20 (83.3%) Med 4 (16.7%) Cardiac 6 (25%) Resp 15 (62.5%) Other 3 (12.5%) p=0.03 p= Primary Outcome Primary Outcome Incidence of opioid withdrawal Unknown WAT-1 scale documented ~18% of the time Limitations: Lack of WAT-1 scores» Separate flow sheet» RN not consistently recording Patient transferred out of PICU 29 14
15 Primary Outcome Prospective patients that finished within their assigned protocol < 5 days N=3 (50%) 6-10 days N=3 (50%) days N=0 (0%) 10 day wean N=6 20 day wean N=14 < 5 days N=3 (21%) 6-10 days N=5 (36%) days N=6 (43%) 30 Results Secondary Outcomes Mean (range) Retrospective (n=62) Prospective (n=20) P-value PICU days (2-229) 21.5 (8-44) p<0.001 Hospital days (4-246) 29.7 (12-51) p<0.001 Taper days (1-111) 9.14 (2-19) p=
16 Doses (0-695) (1-234) Meth/morph Doses 35 (4-78) 40 (0-315) Opioid rescue doses 3.4 (0-15) 12 (0-70) Benzodiazepine doses Retrospective Prospective 32 p=0.97 p<0.001 p<0.001 Additional Results Secondary Outcomes Mean (range) Retrospective (n=62) Prospective (n=20) P-value Benzodiazepine taper concurrently Deceased during taper Yes 18 (29%) No 44 (71%) Yes 6 (9.7%) No 56 (90.3%) Yes 5 (27.9%) No 19 (79.2%) Yes 0 (0%) No 24 (100%) p=0.59 p=0.18 Cost of drug $4.52 ( ) $3.15 ( ) n/a Days on CI prior to wean (5-98) (5-23) p=
17 Conclusion Implementing a morphine weaning protocol in our PICU was associated with significantly decreased: Taper days Opioid/benzodiazepine rescue doses 34 Limitations Lack of WAT-1 scores WAT-1 on a separate nursing flow sheet Transferred out of the PICU prior to completion of morphine wean No patients followed the protocol as written Patients required shorter morphine weans than 10 and 20 days 35 17
18 Future Directions WAT-1 scale on nursing flowsheet/emr Modifying to a 5 and 10 day morphine wean 36 Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential conflict of interest in relation to this presentation 18
4/18/14. Background. Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients. Background. Signs and Symptoms of Withdrawal
Background 1 Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Alyssa Cavanaugh, PharmD PGY1 Pharmacy Resident Children s Hospital of Michigan **The speaker has no actual or
More informationManagement of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal
Management of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal Kirsten H. Ohler, Pharm.D., BCPS Clinical Assistant Professor Neonatal / Pediatric Clinical Pharmacist University of Illinois at
More informationWITHDRAWAL OF ANALGESIA AND SEDATION
WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening drug doses
More informationPrevention and Treatment of Opioid and Benzodiazepine Withdrawal
1.0 Introduction The purpose of this guideline is to ensure that patients who are at risk of developing withdrawal symptoms can be weaned off opioids and benzodiazepines in a timely fashion. It is appropriate
More informationMethadone dosage for prevention of opioid withdrawal in children
Paediatric Anaesthesia 2003 13: 805 810 Methadone dosage for prevention of opioid withdrawal in children RAJASHEKHAR SIDDAPPA MD*, JAMES E. FLETCHER MBBS, ANDREW M.B. HEARD MBChB, DONNA KIELMA RN, MICHAEL
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationIdentifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -2/11/13
Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -// What is Neonatal Abstinence Syndrome? Neonatal withdrawal after intrauterine exposure
More informationTreatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine
Treatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine Background Morphine sulfate has been recommended by the AAP as the first-line agent for the pharmacologic
More informationNEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM
VIDANT MEDICAL CENTER PATIENT CARE _ SUBJECT: Abstinence Scoring NUMBER: A-1 PAGE: 1 OF: 5 _ NEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM POLICY: A thorough evaluation of the infant is required in order
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationSubstance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN
British Columbia Reproductive Care Program Substance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN INTRODUCTION During the antenatal period, the opportunity exists for the primary care
More informationWales Neonatal Network Guideline
Guideline on the Management of Neonatal Abstinence Syndrome Introduction Neonatal Abstinence Syndrome (NAS) is a constellation of symptoms and signs occurring in a baby as a result of withdrawal from physically
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationCHILDREN S SERVICES. Neonatal Abstinence Syndrome
CHILDREN S SERVICES Neonatal Abstinence Syndrome Background Neonatal Abstinence Syndrome (NAS) is a combination of behavioural and physiological signs and symptoms that occur in newborns going through
More informationNEONATAL ABSTINENCE SYNDROME. Osama Naga, M.D. PGY2
NEONATAL ABSTINENCE SYNDROME Osama Naga, M.D. PGY2 Objective: Describe the common causes of NAS Clinical Presentation Diagnosis Identify the different scoring system for pharmacologic therapy Minimize
More informationNurses Self Paced Learning Module on Pain Management
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationCare Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationIntroduction to Neonatal Abstinence Syndrome
Introduction to Neonatal Abstinence Syndrome Cara Christ, MD Director, Arizona Department of Health Services Learning Objectives 1.Define Neonatal Abstinence Syndrome 2.Describe Neonatal Abstinence Syndrome
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationWithdrawal symptoms in long term sedation exposure of pediatric intensive care patients
CLINICAL PRACTICE Withdrawal symptoms in long term sedation exposure of pediatric intensive care patients Susanne Kotz University Medical Center Hamburg-Eppendorf, Germany Correspondence: Susanne Kotz.
More informationSupported Alcohol Withdrawal Treatment Information
Supported Alcohol Withdrawal Treatment Information Alcohol Liaison Service What is Alcohol Withdrawal Syndrome? If you are dependent on alcohol and suddenly stop drinking or you are admitted to hospital
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
More informationSymptom Based Alcohol Withdrawal Treatment
Symptom Based Alcohol Withdrawal Treatment -Small Rural Hospital- Presenter CDR Dwight Humpherys, DO dwight.humpherys@ihs.gov Idaho State University Baccalaureate Nursing Program Lake Erie College of Osteopathic
More informationNeonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines
Neonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines 1. Neonatal Drug Withdrawal Intrauterine exposure to certain drugs and medications can cause clinical symptoms in the
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More information(peak at 2 days 6 wks)
Perinatal Manual of Southwestern Ontario A collaboration between the Regional Perinatal Outreach Program of Southwestern Ontario & the Southwestern Ontario Perinatal Partnership (SWOPP) Chapter 46 NEONATAL
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationAcute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction June 9, 2011 Tufts Health Care Institute Program on Opioid Risk Management Daniel
More informationSubstance Abuse lifestyle Concern for mother - fetus - and - neonate
OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand the pros and cons associated with each medication Understand
More informationCONTROLLED SUBSTANCE CONTRACT
CONTROLLED SUBSTANCE CONTRACT The purpose of this contract is to protect my access to controlled substances and to protect our ability to prescribe for you. The long-term use of substances such as opiates
More informationWorkshop: Management of Depression in the Primary Care Setting, Kaiser Permanente of Ohio s Multidisciplinary Model
Workshop: Management of Depression in the Primary Care Setting, Kaiser Permanente of Ohio s Multidisciplinary Model Larissa Elgudin, MD, Chief of Behavioral Health Services Colleen O Malley RN, BSN, Regional
More informationMODERATE SEDATION RECORD (formerly termed Conscious Sedation)
(POLICY #DOC-051) Page 1 of 6 WELLSPAN HEALTH - YORK HOSPITAL NURSING POLICY AND PROCEDURE Dates: Original Issue: September 1998 Annual Review: March 2012 Revised: March 2010 Submitted by: Brenda Artz
More informationMEDICATION ABUSE IN OLDER ADULTS
MEDICATION ABUSE IN OLDER ADULTS Clifford Milo Singer, MD Adjunct Professor, University of Maine, Orono ME Chief, Division of Geriatric Mental Health and Neuropsychiatry The Acadia Hospital and Eastern
More informationPhenobarbital in Severe Alcohol Withdrawal Syndrome. Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy
Phenobarbital in Severe Alcohol Withdrawal Syndrome Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy Disclosure: No relevant financial relationship exists. Objectives 1. Describe the pathophysiology
More informationSAFE PAIN MEDICATION PRESCRIBING GUIDELINES
Prescription drug abuse has been declared an epidemic by the Centers for Disease Control. According to 2012 San Diego Medical Examiner data, the number one cause of non-natural death is due to drug overdoses
More information4/13/15. Case 1. COWS = Clinical Opioid Withdrawal Scale. Special Populations
Special Populations ACMT Addiction Academy Faculty Panelists 1 Case 1 The Toxicology service is consulted from the ED as the county jail has brought in a 21 year-old Hispanic woman who is 18 weeks pregnant.
More informationSubstitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
More informationOpioid Agreement for Center for Pain Management S.C.
Opioid Agreement for Center for Pain Management S.C. Patient Name: DOB: I am the patient named above. I have agreed to use pain medication as part of my treatment for chronic pain. I understand that these
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationNaloxone treatment of opioid overdose
Naloxone treatment of opioid overdose Opioids Chemicals that act in the brain to relieve pain, often use to suppress cough, treat addiction, and provide comfort After prolonged use of opioids, increasing
More informationHow To Treat An Alcoholic Patient
Height Weight Allergies If appropriate for patient condition, please consider the following order sets: Initiate Electrolyte Replcement: Med/Surg, Med/Surg Tele Physician Order #842 Discontinue all lorazepam
More informationPain, Addiction & Methadone
Pain, Addiction & Methadone A CHALLENGING INTERFACE METHADONE AND SUBOXONE OPIOID SUBSTITUTION CONFERENCE Objectives 2 Explore the interface between concurrent pain and addiction. Appreciate the challenges
More informationElectronic Medical Record (EMR) Safety Results of CAH Testing. Tom Johns, PharmD Shands at the University of Florida
Electronic Medical Record (EMR) Safety Results of CAH Testing Tom Johns, PharmD Shands at the University of Florida Vendors Evaluated CPSI Healthland Cerner Test Patients Test Patient A Age: 76 y/o Sex:
More informationNeonatal Abstinence Syndrome (NAS)
Women and Newborn Health Service King Edward Memorial Hospital Neonatal Abstinence Syndrome (NAS) W O M E N A N D N E W B O R N drug and alcohol service (wandas) Delivering a Healthy WA Neonatal Abstinence
More informationTeen Misuse and Abuse of Alcohol and Prescription Drugs. Information for Parents
Teen Misuse and Abuse of Alcohol and Prescription Drugs Information for Parents Terminology Misuse: Using a drug in a way in which it was not intended Example: Using a higher dose of medication than was
More informationOpiate Treatment for Aboriginal High School Students in Ontario
Opiate Treatment for Aboriginal High School Students in Ontario January 2014 1 CHALLENGE About 40% of the students at an Aboriginal high school in Thunder Bay Ontario (Canada) are known to be addicted
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationFinancial Disclosures
Opioid Agonist Therapy: To Maintain or Not To Maintain - A Case Discussion PCSS-MAT American Psychiatric Association Drs. Ed Salsitz, John Renner, Timothy Fong April 14, 2015 Financial Disclosures Edwin
More informationSubstance Abuse During Pregnancy: Moms on Meds. Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates
Substance Abuse During Pregnancy: Moms on Meds Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates 2010 National Survey on Drug Use and Health An estimated 4.4% of pregnant women reported
More informationGuidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION
1145 W. Diversey Pkwy. 773-880-1460 Chicago, Illinois 60614 www.ncchc.org Guidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION NCCHC issues guidance to assist correctional health
More informationPOLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL
PURPOSE POLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL To outline the procedures used in recognizing and providing
More informationAlcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
More informationLidocaine Infusion for Perioperative Pain Management. Marley Linder, PharmD Matt McEvoy, MD
Lidocaine Infusion for Perioperative Pain Management Marley Linder, PharmD Matt McEvoy, MD Perioperative Surgical Home: PCS Shared Goals Improved Outcomes (pain, PONV, LOS, SSI) Improve Throughput (Clinic
More informationChallenges of Foster Parents who Care for Infants with Neonatal Abstinence Syndrome
Challenges of Foster Parents who Care for Infants with Neonatal Abstinence Syndrome All Health Care Providers are required by law to make a referral to the Department of Children s Services (DCS) Child
More informationSaint Thomas Hospital Protocol. Protocol Title: Terminal Weaning from Ventilator Protocol No.: V-09. Medical Staff departments
Saint Thomas Hospital Protocol Protocol No.: V-09 Operating Unit(s) Medical Staff departments Important s: Affected: affected:! Hospital! Medicine of Origin: 2/00 " Regional Network! Surgery Reviewed:
More informationWhat is Methadone? Opioid Treatment Programs Today. Is Methadone Safe? Pain Clinics. Wisconsin OTPs. Methadone Maintenance Treatment 5/6/2013
Methadone Maintenance Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority April 22, 2013 What is Methadone? Schedule II pharmaceutical opioid similar to Oxycodone or morphine. Binds to the
More informationGeneral PROVIDER INITIALS: PHYSICIAN ORDERS
Height Weight Allergies If appropriate for patient condition, please consider the following order sets: Initiate Electrolyte Replcement: Med/Surg, Med/Surg Tele Physician Order #842 General Vital Signs
More informationUniversity of Michigan Alcohol Withdrawal Guidelines Overview
University of Michigan Alcohol Withdrawal Guidelines Overview The following document contains the University of Michigan Alcohol Withdrawal Guidelines. These guidelines were developed through an intensive
More informationUNIT VIII NARCOTIC ANALGESIA
UNIT VIII NARCOTIC ANALGESIA Objective Review the definitions of Analgesic, Narcotic and Antagonistic. List characteristics of Opioid analgesics in terms of mechanism of action, indications for use and
More informationOpioid Addiction & Methadone Maintenance Treatment. What is Methadone? What is an Opioid?
Opioid Addiction & Methadone Maintenance Treatment Dr. Nick Wong MD, CCFP AADAC Edmonton ODP AADAC AHMB Concurrent Disorder Series September 13, 2007 1 What is Methadone? What is methadone? Synthetic opioid.
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationOPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
More informationCurrent Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010 Substance Exposed Newborns Alcohol Tobacco Caffeine Amphetamines Cocaine Barbituates Selective Serotonin Re-uptake
More informationAlcohol Withdrawal Syndromes
Alcohol Withdrawal Syndromes Should You Treat This Patient s Alcohol Withdrawal With Benzodiazepines?! Meta-analysis of RCTs of benzodiazepines for the treatment of alcohol withdrawal! 11 RCTs identified,
More informationAcute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC
Acute Pain Management in the Opioid Dependent Patient Maripat Welz-Bosna MSN, CRNP-BC Relieving Pain in America (IOM) More then 116 Million Americans have pain the persists for weeks to years $560-635
More informationCollaborative Practice Agreement for Nurse Practitioner Management of Patients in the Specialty of Pediatric Critical Care
Collaborative Practice Agreement for Nurse Practitioner Management of Patients in the Specialty of Pediatric Critical Care Purpose Section I Introduction/Overview This document authorizes the nurse practitioner
More informationHow To Know If You Should Be Treated
Comprehensive ehavioral Care, Inc. delivery system that does not include sufficient alternatives to a particular LOC and a particular patient. Therefore, CompCare considers at least the following factors
More informationCARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy
Page 1 of 5 INDICATIONS EXCLUSIONS 2 consecutive blood glucose measurements greater than 110 mg per dl AND NPO with a continuous caloric source AND Diagnosis of : Cardio-thoracic Surgery NOTE: This protocol
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationWithdrawal Symptoms: How Long Do They Last?
Withdrawal Symptoms: How Long Do They Last? Posted by First Step Medical Detox on November 24, 2015 When considering stopping drugs or alcohol, many addicts and alcoholics are concerned about the withdrawal
More informationPhilip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
More informationOctober 2012. We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely,
October 2012 he Knowledge and Attitudes Survey Regarding Pain tool can be used to assess nurses and other professionals in your setting and as a pre and post test evaluation measure for educational programs.
More informationNeonatal Abstinence Syndrome. A Guide for Families
Neonatal Abstinence Syndrome A Guide for Families Contents What is Neonatal Abstinence Syndrome (NAS)?...................... 4 When will my baby show signs of NAS?..................................................
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationInformation for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
More informationClinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationNHS FORTH VALLEY Management of Neonatal Abstinence Syndrome
NHS FORTH VALLEY Management of Neonatal Abstinence Syndrome Date of First Issue 25/10/2011 Approved 25/11/2011 Current Issue Date 30/11/2011 Review Date 30/11/2013 Version 1.00 EQIA Yes 06/12/2011 Author
More informationAfter seeing a patient on a Diversion Alert installment..
After seeing a patient on a Diversion Alert installment.. Recommendations from Dr. James Berry of Mercy Recovery Center OVERVIEW OF DIVERSION Manufacture Distribution Pharmacy Patient End -user OPPORTUNITIES
More informationNALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT
NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT Opioid dependence is a devastating and frequently fatal medical condition. It is a manifestation of addictive disorder
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationBackground & Significance
The Impact Of A Structured Opioid Renewal Clinic On Aberrant Drug Behavior Outcomes At A Northeastern VA Medical Center Salimah H. Meghani, PhD, MBE, CRNP Assistant Professor, University of Pennsylvania
More informationJames Bell May 2011 GBL
James Bell May 2011 GBL Day 1 M 32, lives alone, data analyst 12 noon - presented CDAT seeking help - wrong borough, referred to local service - went home, agitated and hallucinating - Took large dose
More informationDepartment of Pharmacy, Kaiser Permanente San Francisco Medical Center, San Francisco 94115, California, USA
Journal of Pharmacy and Pharmacology 3 (2015) 33-38 doi: 10.17265/2328-2150/2015.01.005 D DAVID PUBLISHING Evaluation of Glycemic Control with a Pharmacist-Managed Post-Cardiothoracic Surgery Insulin Protocol
More informationA Comparison of Costs Between Medical and Surgical Patients in an Academic Pediatric Intensive Care Unit
ORIGINAL RESEARCH A Comparison of Costs Between Medical and Surgical Patients in an Academic Pediatric Intensive Care Unit Benson S. Hsu, MD, MBA; Thomas B. Brazelton III, MD, MPH ABSTRACT Objective: To
More informationHospital Management of Opioid Dependence. Dependence. Disclosure. Pharmacologic Management. Methadone Utilization. Hospital Management of Opioid
Disclosure Hospital Management of Opioid Dependence Attended Buprenorphine advisory board meeting (Schering Canada) May 2007, but personal honorarium/compensation was declined Dr. Alex Chan alexchchan@hotmail.com
More informationAppendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
More informationDowners/Depressants (pages 40-50)
Downers/Depressants (pages 40-50) Read pages 49-54, 59-60, and 78-79 of the booklet, Street Drugs. Pages 40-50 of the text. Narcotics: Prescription Origin: Southeast Asia, Southwest Asia, and in the Western
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationMedication-Assisted Treatment (MAT) & What It Means Long-Term Gary K. Byrd., M.Ed., MAC, CCS, CAMS Methadone is the Gold Standard for treatment of chronic heroin addiction Gary Byrd 2015 1 Gary Byrd 2015
More informationStuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas
Billing and Coding in Neurology and Headache Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas CPT Codes vs. ICD Codes Category
More informationMedication is not a part of treatment.
Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained
More informationA Prospective Pilot Study Describing the Use of Performance-Enhancing Drugs in Adolescent and Young Adult (AYA) Male Oncology Patients
Clinical Research Rotation The IRB Protocol A Prospective Pilot Study Describing the Use of Performance-Enhancing Drugs in Adolescent and Young Adult (AYA) Male Oncology Patients Version 1.0 (rev 9/20/2012)
More information